Patent US4308257A successfully refreshed from Google Patents.
US4308257A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Accelerating cellular repair composition for the human body and method of administering same
Assignee: Individual
•
Filing: 1980-06-03
•
Granted: 1981-12-29
•
Expires: 2000-06-03
Abstract
Abstract The present invention comprises a composition of matter and method for introducing the composition of matter into the human body to achieve cellular repair. The composition comprises as a first component a stable, pyrogen-free liquid mixture containing an amino acid metabolite, a thiamine salt, diphosphopyridine nucleotide, diaphorase flavin protein enzyme, and a carrier in select ratios, and as a second component an enteric coated tablet comprising nicotineamide, adenosine-5-monophosphate, diphosphopyridine nucleotide, and an inert carrier in select ratios. The first component is administered by subcutaneous injection, followed by ingestion of the second component. This invention is particularly useful in healing ulcers, burns, post-operative wounds, and various skin disruptions of diabetics.
Inventors
- 👤 Saul Caspe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 12:56
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/20; A61K9/28
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
236 words
A two-part system for accelerating cellular repair comprising an injectible liquid mixture formulated to produce an initial positive response to certain abnormal metabolic conditions comprising: (A) (a) an amino acid metabolite selected from the group consisting of arginine, creatine, and mixtures thereof in a concentration from between about 0.025% and about 0.075% by weight, (b) a thiamine salt in a concentration from between about 0.1% and about 0.2% by weight, (c) diphosphopyridine nucleotide in a concentration from between about 0.06% and about 0.11% by weight, (d) diaphorase flavin protein enzyme at an activity from between about 0.0001% and about 0.0003% by weight derived from animal muscles and characterized by the presence of a protein moiety that promotes respiratory activity on cells, and (e) the remainder an inert carrier; wherein: (1) the weight ratio of the amino acid metabolite to the thiamine salt is from between about 0.05:0.15 and about 0.075:0.2; (2) the weight ratio of diphosphopyridine nucleotide to diaphorase flavin protein enzyme is from between about 0.06:0.0001 and about 0.11:0.0003, and (3) the concentration of diaphroase flavin protein enzyme per ml. of tissue substrate is from between about 0.78 ug. and about 0.39 ug.; and (B) a respiratory enzyme booster tablet which will produce a maintenance response to abnormal metabolic conditions comprising an enteric coated substance containing a mixture of diphosphopyridine nucleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier wherein the enteric coating is cellulose acetate phthalate.
Claim 2
Dependent Claim
236 words
A two-part system for accelerating cellular repair comprising an injectible liquid mixture formulated to produce an initial positive response to certain abnormal metabolic conditions comprising: (A) (a) an amino acid metabolite selected from the group consisting of arginine, creatine, and mixtures thereof in a concentration from between about 0.025% and about 0.075% by weight, (b) a thiamine salt in a concentration from between about 0.1% and about 0.2% by weight, (c) diphosphopyridine nucleotide in a concentration from between about 0.06% and about 0.11% by weight, (d) diaphorase flavin protein enzyme at an activity from between about 0.0001% and about 0.0003% by weight derived from animal muscles and characterized by the presence of a protein moiety that promotes respiratory activity on cells, and (e) the remainder an inert carrier; wherein: (1) the weight ratio of the amino acid metabolite to the thiamine salt is from between about 0.05:0.15 and about 0.075:0.2; (2) the weight ratio of diphosphopyridine nucleotide to diaphorase flavin protein enzyme is from between about 0.06:0.0001 and about 0.11:0.0003, and (3) the concentration of diaphroase flavin protein enzyme per ml. of tissue substrate is from between about 0.78 ug. and about 0.39 ug.; and (B) a respiratory enzyme booster tablet which will produce a maintenance response to abnormal metabolic conditions comprising an enteric coated substance containing a mixture of diphosphopyridine nucleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier wherein the enteric coating is cellulose acetate phthalate.
Claim 3
Independent Claim
139 words
A method of treating abnormal metabolic conditions comprising: (A) periodically introducing subcutaneously a pyrogen-free, stabilized liquid mixture comprising: (a) an amino acid metabolite selected from the group consisting of arginine, creatine, and mixtures thereof in a concentration from between about 0.025% and about 0.075% by weight, (b) a thiamine salt in a concentration from between about 0.1% and about 0.2% by weight, (c) diphosphopyridine nucleotide in a concentration from between about 0.06% and about 0.11% by weight, (d) diaphorase flavin protein enzyme at an activity from between about 0.0001% and about 0.0003% by weight derived from animal muscles and characterized by the presence of a protein moiety that promotes respiratory activity on cells, and (e) the remainder an inert carrier; and (B) periodically introducing by ingestion an enteric control mixture comprising diphosphopyridine nucleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier.
Claim 4
Independent Claim
139 words
A method of treating abnormal metabolic conditions comprising: (A) periodically introducing subcutaneously a pyrogen-free, stabilized liquid mixture comprising: (a) an amino acid metabolite selected from the group consisting of arginine, creatine, and mixtures thereof in a concentration from between about 0.025% and about 0.075% by weight, (b) a thiamine salt in a concentration from between about 0.1% and about 0.2% by weight, (c) diphosphopyridine nucleotide in a concentration from between about 0.06% and about 0.11% by weight, (d) diaphorase flavin protein enzyme at an activity from between about 0.0001% and about 0.0003% by weight derived from animal muscles and characterized by the presence of a protein moiety that promotes respiratory activity on cells, and (e) the remainder an inert carrier; and (B) periodically introducing by ingestion an enteric control mixture comprising diphosphopyridine nucleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier.
Claim 5
Independent Claim
38 words
A method of treating diabetic wounds and ulcers comprising: (A) periodically introducing subcutaneously a pyrogen-free, stabilized liquid mixture containing diphosphopyridine nucleotide, and (B) periodically introducing by ingestion a mixture comprising diphosphopyridine necleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier.
Claim 6
Independent Claim
38 words
A method of treating diabetic wounds and ulcers comprising: (A) periodically introducing subcutaneously a pyrogen-free, stabilized liquid mixture containing diphosphopyridine nucleotide, and (B) periodically introducing by ingestion a mixture comprising diphosphopyridine necleotide, nicotineamide, adenosine-5-monophosphate, and an inert carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-12-28 | 1985-06-29 | 1985-12-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-12-28 | 1989-06-29 | 1989-12-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-12-28 | 1993-06-29 | 1993-12-29 | $7700.00 | Window Closed / Lapsed |